These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8933625)

  • 1. A new approach to risk assessment integrating scientific evaluation and economic assessment of costs and benefits.
    Barnard RC
    Regul Toxicol Pharmacol; 1996 Oct; 24(2 Pt 1):121-5. PubMed ID: 8933625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Executive Order 12866: advantages and disadvantages of the administration's new regulatory plan on risk, benefit, and costs.
    Barnard RC
    Regul Toxicol Pharmacol; 1996 Jun; 23(3):178-82. PubMed ID: 8812959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementing the Precautionary Principle: incorporating science, technology, fairness, and accountability in environmental, health, and safety decisions.
    Ashford NA
    Int J Occup Med Environ Health; 2004; 17(1):59-67. PubMed ID: 15212207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comments by the Working Group for Methods of Economic Evaluation in Health Care (AG MEG) to IQWiG's Draft Guidelines "Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System"].
    Krauth C; John J; Aidelsburger P; Brüggenjürgen B; Hansmeier T; Hessel F; Kohlmann T; Moock J; Rothgang H; Schweikert B; Seitz R; Wasem J;
    Gesundheitswesen; 2008 Jun; 70(6):e1-16. PubMed ID: 18661452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of noncancer risk assessment approaches for use in deriving drinking water criteria.
    Gibson MC; deMonsabert SM; Orme-Zavaleta J
    Regul Toxicol Pharmacol; 1997 Dec; 26(3):243-56. PubMed ID: 9441915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global cost-benefit analysis of water supply and sanitation interventions.
    Hutton G; Haller L; Bartram J
    J Water Health; 2007 Dec; 5(4):481-502. PubMed ID: 17878562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk characterization: A bridge to informed decision making.
    North DW
    Fundam Appl Toxicol; 1997 Oct; 39(2):81-8. PubMed ID: 9344620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using risk assessment, benefit-cost analysis, and real options to implement a precautionary principle.
    Farrow S
    Risk Anal; 2004 Jun; 24(3):727-35. PubMed ID: 15209941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic valuation through cost-benefit analysis--possibilities and limitations.
    Hansjürgens B
    Toxicology; 2004 Dec; 205(3):241-52. PubMed ID: 15464633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A micro case study of the legal and administrative arrangements for river health in the Kangaroo River (NSW).
    Mooney C; Farrier D
    Water Sci Technol; 2002; 45(11):161-8. PubMed ID: 12171348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Public health and regulatory considerations of the Safe Drinking Water Act.
    Raucher RS
    Annu Rev Public Health; 1996; 17():179-202. PubMed ID: 8724223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated risk assessment and screening analysis of drinking water safety of a conventional water supply system.
    Sun F; Chen J; Tong Q; Zeng S
    Water Sci Technol; 2007; 56(6):47-56. PubMed ID: 17898443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs.
    Jeuland M; Whittington D
    Vaccine; 2009 May; 27(23):3109-20. PubMed ID: 19428925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the costs and benefits of dam construction from a multidisciplinary perspective.
    Brown PH; Tullos D; Tilt B; Magee D; Wolf AT
    J Environ Manage; 2009 Jul; 90 Suppl 3():S303-11. PubMed ID: 18995948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of risk-reduction measures to reach water safety targets.
    Lindhe A; Rosén L; Norberg T; Bergstedt O; Pettersson TJ
    Water Res; 2011 Jan; 45(1):241-53. PubMed ID: 20943244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk proposals of the 103rd Congress.
    Paxman D
    Drug Metab Rev; 1996; 28(1-2):245-67. PubMed ID: 8744601
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost benefit risk--a concept for management of integrated urban wastewater systems?
    Hauger MB; Rauch W; Linde JJ; Mikkelsen PS
    Water Sci Technol; 2002; 45(3):185-93. PubMed ID: 11902470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of tandem mass spectrometry screening in California.
    Feuchtbaum L; Cunningham G
    Pediatrics; 2006 May; 117(5 Pt 2):S280-6. PubMed ID: 16735254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.